Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Technology appraisal
Summary (source: NICE)
Reference: TA1152
Type: Technology appraisal
Published: 7 May 2026
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity is technology appraisal TA1152, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 7 May 2026. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.